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Key facts
•	 HEV is a relevant clinical problem also in industrialized countries
•	 In addition to waterborne infections, zoonotic and blood-borne 
transmissions of HEV occur, HEV may cause chronic infections 
in immunocompromised patients and can be associated with 
extrahepatic symptoms 
•	 Antiviral therapies against HEV are available and a prophylactic 
vaccine has been developed 
Transmission
HEV basics
•	 Spherical positive-stranded RNA virus
•	 Hepevirus within the family of Hepeviridae
•	 One serotype but 5 different genotypes 
(1-4 humopathogenic)
•	 Thermal stability: 70 °C
Diagnosis
Hepatitis E is frequently diagnosed by the 
detection of HEV antibodies followed by testing for 
HEV RNA in blood or stool. However, serological 
assays show a wide variability in sensitivity and 
specificity and HEV antibodies may be negative 
in immunocompromised individuals. Thus, direct 
testing for HEV RNA is advised in all patients [1] 
Major breakthrough and near future
A  major breakthrough in HEV research was the successful development of an 
HEV vaccine (HEV-239) which has been licensed in China in early 2012. This 
vaccine showed a vaccine efficacy of 94-100% in preventing acute symptomatic 
cases of hepatitis E [5]. However, it still needs to be determined if HEV-239 
is also effective in patients with chronic liver disease or subjects receiving 
immunosuppressive medications
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For more than two decades, medical students have learned that hepatitis 
E virus infection causes self-limited acute hepatitis, occasionally 
progressing to fulminant liver failure in distinct risk groups. However, 
emerging data generated during the last five years, clearly showed that 
various aspects of textbook knowledge on hepatitis E have to be revised. 
It became evident that HEV infection has multiple faces with respect to 
chains of infection and during the course of disease. 
The far majority of HEV infections occur in developing countries due 
to waterborne transmission of HEV genotype 1 or 2 [1, 2]. In contrast, HEV 
genotype 3 and 4 infections are mostly foodborne with various animal 
species serving as potential zoonotic reservoirs [1]. Pig meat has been 
identified as a major source of HEV infections in industrialized countries 
and various studies detected HEV RNA in food products purchased in 
grocery stores [1]. In addition, HEV has been detected in deer, rats, 
shellfish, and also on strawberries. HEV is temperature sensitive and 
loses its ability to infect target cells after exposure to more than 70 °C. 
It is therefore strongly recommended that people at risk should avoid 
consuming raw meat or other food products potentially exposed to HEV. 
Moreover, close contact with certain animals may represent a risk factor 
for HEV. Patient to patient transmission of HEV has also been reported. 
Of note, sewage samples from different European countries and the 
United States tested positive for HEV RNA. A largely under-recognized 
cause of HEV infection may be transmission by HEV contaminated 
blood products. Plasma products analyzed in Germany tested HEV 
RNA positive in 10% of cases [3]. In single cases, HEV may even be 
transmitted by solid organ transplantation [4].   
In many centres, diagnostic algorithms of hepatitis E testing rely 
on detection of HEV antibodies, followed by testing for HEV RNA in 
blood or stool. However, serological assays show a wide variability in 
sensitivity and specificity and HEV antibodies may be negative in immune 
compromised individuals. Thus, direct testing for HEV RNA is advised 
in all patients, if HEV infection is suspected as the cause of hepatitis 
that cannot be explained by other reasons [1].  
HEV infection shows a wide spectrum of clinical manifestations. 
In most settings, less than one out of hundreds of infections lead to 
clinically symptomatic acute hepatitis [5]. More severe courses of acute 
hepatitis E have been described in individuals with pre-existing chronic 
liver disease, elderly men and pregnant women. In the latter, distinct 
genetic polymorphisms may contribute to the severity of hepatitis [6]. 
The WHO estimates that more than 3 million individuals suffer from 
acute symptomatic hepatitis E each year, leading to about 70,000 
annual deaths [7]. 
Immune competent individuals almost always clear the infection 
within 6 weeks. In immunosuppressed patients, including organ transplant 
recipients and HIV-infected subjects, HEV infection may take a chronic 
course, leading to progressive liver disease in some patients. The severity 
of chronic hepatitis E has been highlighted by various case reports of 
HEV-associated liver cirrhosis followed by organ failure. HEV specific 
adaptive immunity has been correlated with the control of HEV infection, 
and the level of immunosuppression increases the risk of chronicity [8]. 
The use of distinct immunosuppressive compounds may also influence 
the likelihood of HEV clearance. While one retrospective study associated 
the administration of tacrolimus with chronicity [9], another prospective 
investigation suggested more frequent recoveries in a small series of 
heat-transplanted patients treated with mycophenolate [10]. However, 
these findings are still preliminary and further studies are required to 
investigate whether specific immunosuppressive drugs alter the course 
of HEV infection. 
Different options to treat chronic hepatitis E have been proposed, 
including reduction of immunosuppressive medication (if possible), 
administration of interferon alpha or usage of ribavirin monotherapy [1, 
2]. The optimal dose and duration of ribavirin therapy still need to be 
defined, but 600-1000 mg daily for 3-5 months was suggested. Shorter 
therapies and dose reductions have been associated with virological 
relapses or breakthroughs [1, 2, 10], and thus, should be avoided.   
An unexpected and possibly frequently overlooked face of HEV 
infection is the association with various extrahepatic disorders. Immune 
phenomena have been described both during the acute and chronic 
viraemic phases and after recovery of infection. Specifically, cases of 
Guillaune Barre, glomerulonephritis and cryoglobulinemia occurred in 
the context of HEV infections. However, the frequency of extrahepatic 
manifestations of hepatitis E is completely unknown and the underlying 
pathomechanisms are not defined yet [1]. 
A major breakthrough in HEV research was the successful 
development of an HEV vaccine, which has been licensed in China 
in early 2012. The vaccine HEV-239, which is based on recombinant 
HEV genotype 1 antigen, showed a vaccine efficacy of 94-100% in 
preventing acute symptomatic cases of hepatitis E [5]. The vaccine 
also showed cross-genotype efficacy, since genotype 4 infections 
were prevented with a genotype 1-based vaccine. However, it still 
needs to be determined whether HEV-239 is also effective in patients 
with chronic liver disease or subjects receiving immunosuppressive 
medications. Moreover, the long-term safety and immunogenicity 
need to be determined. HEV 239 will hopefully become available also 
outside of China in the near future; in particular as no alternative HEV 
vaccine program has reached phase 3 clinical trials. 
In summary, the overall relevance of HEV infection has been 
underestimated for many years. Clinical textbooks need to be updated 
and should consider recent advances: 
(i) HEV is a relevant global health problem and also occurs 
in industrialized countries
(ii) In addition to waterborne infections, zoonotic and blood-
borne transmission of HEV occurs 
(iii) HEV may cause chronic infections in immune 
compromised patients and can be associated with 
extrahepatic symptoms
(iv) Antiviral therapies against HEV are available and a 
prophylactic vaccine has been developed
© 2012 European Association for the Study of the Liver. Published by 
Elsevier B.V. All rights reserved. 
Financial support
Support by the German Federal Ministry of Education and Research 
(reference number: 01EO0802) and by a grant from the Robert Koch 
Institute on hepatitis E to Sven Pischke and Heiner Wedemeyer 
(reference number 1362-1097). 
Conflict of interest
The authors declared that they do not have anything to disclose 
regarding funding or conflict of interest with respect to this manuscript.
Acknowledgements
The authors thank Dr. Svenja Hardtke (Hannover Medical School) for 
editorial assistance.
References
[1]  Wedemeyer H, Pischke S, Manns MP. Pathogenesis and Treatment of Hepatitis E 
Virus Infection. Gastroenterology 2012;142:1388-1397 e1381.
[2]  Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, et al. Hepatitis E. 
Lancet 2012;379:2477-2488.
[3]  Baylis SA, Koc O, Nick S, Blümel J. Widespread distribution of hepatitis E virus in 
plasma fractionation pools. Vox Sang 2011;102:182-183.
[4]  Schlosser B, Stein A, Neuhaus R, Pahl S, Ramez B, Krüger DH, et al. Liver transplant 
from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the 
recipient. J Hepatol 2012;56:500-502.
[5]  Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety 
of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, 
double-blind placebo-controlled, phase 3 trial. Lancet 2010;376:895-902.
[6]  Bose PD, Das BC, Kumar A, Gondal R, Kumar D, Kar P, et al. High viral load and 
deregulation of the progesterone receptor signaling pathway: Association with Hepatitis 
E-related poor pregnancy outcome. J Hepatol 2011;54:1107-1113.
[7]  Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of 
hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012;55:988-997.
[8]  Suneetha PV, Pischke S, Schlaphoff V, Grabowski J, Fytili P, Gronert A, et al. Hepatitis 
E virus (HEV)-specific T-cell responses are associated with control of HEV infection. 
Hepatology 2012;55:695-708.
[9]  Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, et al. Factors 
associated with chronic hepatitis in patients with hepatitis e virus infection who have 
received solid organ transplants. Gastroenterology 2011;140:1481-1489.
[10]  Pischke S, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, et al. Chronic hepatitis 
E in heart transplant recipients. Am J Transplant 2012;12:3128-3133
Journal of Hepatology 2013 vol  58 | 1045—10461046
